XML 16 R5.htm IDEA: XBRL DOCUMENT v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Common Stock
At the market offering
Common Stock
Public offering
Common Stock
Additional Paid-in Capital
At the market offering
Additional Paid-in Capital
Public offering
Additional Paid-in Capital
Accumulated Deficit
At the market offering
Public offering
Total
Balance at the beginning at Dec. 31, 2024     $ 4     $ 403,024 $ (431,597)     $ (28,569)
Balance at beginning (in shares) at Dec. 31, 2024     555,511              
Net Income (Loss)             (2,085)     (2,085)
Issuance of shares and reclassification of liability related to cashless warrant exercises     $ 5     6,884       6,889
Issuance of shares and reclassification of liability related to cashless warrant exercises (in shares)     10,869,856              
Issuance of shares       $ 168       $ 168    
Issuance of shares (in shares) 218,419                  
Stock-based compensation expense           3,725       3,725
Balance at the ending at Sep. 30, 2025     $ 9     413,801 (433,682)     (19,872)
Balance at ending (in shares) at Sep. 30, 2025     11,643,786              
Balance at the beginning at Jun. 30, 2025     $ 9     413,283 (429,144)     (15,852)
Balance at beginning (in shares) at Jun. 30, 2025     11,537,870              
Net Income (Loss)             (4,538)     (4,538)
Issuance of shares and reclassification of liability related to cashless warrant exercises           20       20
Issuance of shares       84       84    
Issuance of shares (in shares) 105,916                  
Stock-based compensation expense           414       414
Balance at the ending at Sep. 30, 2025     $ 9     413,801 (433,682)     (19,872)
Balance at ending (in shares) at Sep. 30, 2025     11,643,786              
Balance at the beginning at Dec. 31, 2025     $ 9     415,783 (470,819)     $ (55,027)
Balance at beginning (in shares) at Dec. 31, 2025     12,105,902             12,105,902
Net Income (Loss)             (10,483)     $ (10,483)
Issuance of pre-funded warrants related to PIPE financing           13,437       13,437
Issuance of shares   $ 3   $ 2,551 $ 13,722     $ 2,551 $ 13,725  
Issuance of shares (in shares) 2,282,929 22,547,701           2,282,929    
Issuance of shares related to exchange of convertible notes     $ 1     31,488       31,489
Issuance of shares related to exchange of convertible notes (in shares)     11,918,380              
Issuance of shares related to exercises of pre-funded and true up warrants     $ 1             1
Issuance of shares related to exercises of pre-funded and true up warrants (in shares)     10,229,763              
Modification of cash-settled restricted stock units           1,952       1,952
Stock-based compensation expense           4,741       4,741
Balance at the ending at Sep. 30, 2026     $ 14     483,674 (481,302)     $ 2,386
Balance at ending (in shares) at Sep. 30, 2026     59,084,675             59,084,675
Balance at the beginning at Jun. 30, 2026     $ 10     468,396 (483,767)     $ (15,361)
Balance at beginning (in shares) at Jun. 30, 2026     26,307,211              
Net Income (Loss)             2,465     2,465
Issuance of shares   $ 3     $ 13,722       $ 13,725  
Issuance of shares (in shares)   22,547,701           0    
Issuance of shares related to exercises of pre-funded and true up warrants     $ 1             1
Issuance of shares related to exercises of pre-funded and true up warrants (in shares)     10,229,763              
Stock-based compensation expense           1,556       1,556
Balance at the ending at Sep. 30, 2026     $ 14     $ 483,674 $ (481,302)     $ 2,386
Balance at ending (in shares) at Sep. 30, 2026     59,084,675             59,084,675